Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on In-stent Restenosis.

Magdi M. El-Omar1, George Dangas, Ioannis Iakovou

  • 1Cardiovascular Research Foundation, and Lenox Hill Heart and Vascular Institute, 55 East 59th Street, 6th Floor, New York, NY 10022, USA. rmehran@crf.org

Current Interventional Cardiology Reports
|November 7, 2001
PubMed
Summary

In-stent restenosis (ISR) remains a challenge after stenting, progressing through distinct phases. Prevention strategies, including drug-eluting stents, are key to reducing ISR incidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart Failure Pharmacotherapy Across the TAVR Continuum.

Journal of cardiac failure·2026
Same author

Balloon-Expandable Versus Self-Expanding Valves in Patients With Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same author

SGLT-2 Inhibitors and Outcomes After Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Neutrophil-to-lymphocyte ratio in patients with low-flow aortic stenosis undergoing transcatheter aortic valve implantation.

Journal of cardiology·2026
Same author

Prognostic Impact of Combined Inflammatory Markers in Patients Undergoing Percutaneous Coronary Intervention.

American heart journal·2026
Same author

Optimal medical therapy in patients with chronic coronary syndrome undergoing PCI: Temporal trends and outcomes.

The American journal of medicine·2026

Area of Science:

  • Cardiovascular Research
  • Interventional Cardiology

Background:

  • In-stent restenosis (ISR) is a significant clinical issue despite stent use.
  • ISR typically manifests within 3-6 months post-stenting and involves thrombosis, inflammation, proliferation, and remodeling.

Purpose of the Study:

  • To review the pathophysiology, predictors, and prevention of in-stent restenosis.
  • To highlight current and emerging strategies for managing ISR.

Main Methods:

  • Review of literature on ISR pathogenesis and clinical outcomes.
  • Analysis of factors influencing ISR development and prognosis.
  • Evaluation of preventive therapeutic modalities.

Main Results:

  • Platelets and macrophages are key drivers of neointimal hyperplasia in ISR.
  • Angiographic patterns, stent length, and minimal lumen diameter predict ISR outcomes.
  • No cure exists, but prevention is paramount.

Conclusions:

  • Intracoronary radiation therapy shows promise for ISR prevention.
  • Drug-eluting stents are expected to significantly reduce ISR incidence.
  • Ongoing research focuses on novel technologies to further mitigate ISR.

Related Experiment Videos